Extraluminal regulation of the growth and repair of tubular structures in vivo
First Claim
1. A method of regulating repair of a wall of luminal tissue following injury at a location on said wall, said method comprising,administering outside said luminal tissue wall at said location, a biocompatible compound-releasing system, said biocompatible compound-releasing system releasing a smooth muscle cell antiproliferative agent into said wall at said location, said releasing taking place over a period of at least 24 hours and being characterized by a rate and a dosage that is selected to be:
- a) high enough to control proliferation of smooth muscle cells in said wall at said location; and
b) low enough to substantially avoid systemic levels of said agent that are high enough to control proliferation of smooth muscle cells at a location remote from said location.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of regulating repair in a physiological system following injury to the lumen of a tubular structure in that system, and of testing the effectiveness of regulatory agent, is presented. The method includes administering a modulator of cell or tissue growth to an extraluminal site adjacent the injured tissue. Administration of substances such as heparin over sustained, prolonged periods controls intimal hyperplasia and smooth muscle cell proliferation, even at doses that are insufficient to have such a beneficial effect if administered systemically. Bolus administration of such compounds at higher doses typically used to achieve systemic effects may have no effect or may even produce adverse effects.
73 Citations
24 Claims
-
1. A method of regulating repair of a wall of luminal tissue following injury at a location on said wall, said method comprising,
administering outside said luminal tissue wall at said location, a biocompatible compound-releasing system, said biocompatible compound-releasing system releasing a smooth muscle cell antiproliferative agent into said wall at said location, said releasing taking place over a period of at least 24 hours and being characterized by a rate and a dosage that is selected to be: -
a) high enough to control proliferation of smooth muscle cells in said wall at said location; and b) low enough to substantially avoid systemic levels of said agent that are high enough to control proliferation of smooth muscle cells at a location remote from said location. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
Specification